Hahn-Jun Lee, M.Sc., Ph.D. is a serial entrepreneur who founded Epygenix Therapeutics, Inc. which develops precision medicines for rare and intractable pediatric genetic epilepsy. He also founded Curyx Bio, Inc. to develop disease modifying drugs for neurodegenerative diseases, inborn errors of metabolism, and autoimmune diseases, Polaryx Therapeutics, Inc which develops patient-friendly medicines for lysosomal storage disorders, Focus Therapeutics, L.L.C., a business catalyst in the biotech-pharma industry, and Medeoryx, Ltd, a cell and gene therapy company converting fibroblast to endothelial, pancreatic, and neuronal cells using both proprietary antisense oligomers and Tissue Nano-Transfection (TNT), and applying to ischemic diseases and to diabetic ulcers.
He has an extensive experience in R&D, deal making, business development, and consulting for several top-notch health care venture capital firms and global pharma and biotech companies, including Doman Associates, Shire Human Genetic Therapies, P&G Pharma, Melior Discovery, CDI, etc. He also has consulted for several Korean biotechs, venture capital firms, and research institutes.
Dr. Lee was an Assistant Professor of Biotechnology in the Department of Orthopedic Surgery, College of Physicians and Surgeons, Columbia University in the city of New York. He also worked as a Staff Scientist at the RIKEN Brain Science Institute in Japan.
He obtained B.S. in Life Science from Sogang University, Seoul, Korea. He completed his M.S. and Ph.D. in applied biotechnology in the Department of Applied Biotechnology at the University of Tokyo, Japan.